Butterfly Network Partners With Merge Labs on Ultrasound BCI
BURLINGTON, Mass. & NEW YORK, September 1, 2026 Butterfly Network, Inc. and Merge Labs have entered a multi-year licensing...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BURLINGTON, Mass. & NEW YORK, September 1, 2026 Butterfly Network, Inc. and Merge Labs have entered a multi-year licensing...
AKRON, Ohio, August 18, 2026 Resivant Medical announced the successful completion of the first patient cases using its Cutivaâ„¢...
VAN NUYS, Calif., August 18, 2026 Kandu, Inc. announced the publication of results from BCI-REHAB, the first randomized controlled...
Beijing, China, August,11, 2026 Datasea Intelligent Technology Ltd. has announced that its variable interest entity, Shuhai Jingwei (Shenzhen) Information...
BETHESDA, Md., June 20, 2026 Researchers supported by the National Institutes of Health (NIH) have achieved a groundbreaking milestone...
